Larimar Therapeutics, Inc.
General ticker "LRMR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $315.4M (TTM average)
Larimar Therapeutics, Inc. follows the US Stock Market performance with the rate: 1.1%.
Estimated limits based on current volatility of 4.0%: low 3.63$, high 3.94$
Factors to consider:
- Total employees count: 65 (+54.8%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Regulatory and compliance, Clinical trial failure, Capital shortage, Manufacturing supply issues, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.52$, 6.74$]
- 2026-12-31 to 2027-12-31 estimated range: [2.41$, 6.43$]
Financial Metrics affecting the LRMR estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: 42.57 < Shareholder equity ratio, % of 53.54 <= 64.23
- Positive: Investing cash flow per share per price, % of 36.16 > -0.60
- Negative: negative Net income
Short-term LRMR quotes
Long-term LRMR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $41.76MM | $90.89MM | $172.50MM |
| Operating Income | $-41.76MM | $-90.89MM | $-172.50MM |
| Non-Operating Income | $4.81MM | $10.29MM | $6.82MM |
| R&D Expense | $27.67MM | $73.28MM | $154.22MM |
| Income(Loss) | $-36.95MM | $-80.60MM | $-165.67MM |
| Net Income(Loss)* | $-36.95MM | $-80.60MM | $-165.67MM |
| Stockholders Equity | $81.72MM | $171.81MM | $78.08MM |
| Assets | $95.94MM | $200.22MM | $145.84MM |
| Operating Cash Flow | $-33.46MM | $-70.76MM | $-113.20MM |
| Capital expenditure | $0.16MM | $0.52MM | $0.09MM |
| Investing Cash Flow | $33.35MM | $-85.39MM | $100.31MM |
| Financing Cash Flow | $0.03MM | $161.88MM | $65.09MM |
| Earnings Per Share** | $-0.84 | $-1.32 | $-2.27 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.